Cygnus Capital Advisors’s Wave Life Sciences WVE Stock Holding History

Cygnus Capital Advisors’s Portfolio WVE Stock Details WVE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-271	Closed	-$5	–	184
2025 Q4	$5	Buy	+271	New	+$2.75K	﹤0.01%	143

Other funds holding WVE

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

GSK plc London $602M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Cygnus Capital Advisors's WVE Position: Q1 2026 in Review

Cygnus Capital Advisors sold out of Wave Life Sciences (WVE) in Q1 2026, closing a stake of 271 shares — an estimated $5 sold.

Cygnus Capital Advisors first reported a position in WVE in Q4 2025 and held it in 1 quarter. The position peaked at $5 in Q4 2025. 232 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

Cygnus Capital Advisors reported no remaining Wave Life Sciences position as of Q1 2026 after selling out during the quarter.
Cygnus Capital Advisors sold 271 Wave Life Sciences shares in Q1 2026, an estimated $5.
Cygnus Capital Advisors first reported a position in Wave Life Sciences in Q4 2025 and held it in 1 quarter.
Cygnus Capital Advisors's Wave Life Sciences position peaked at $5 in Q4 2025.
232 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.